Proactive Investors - Run By Investors For Investors

Summit Therapeutics chief hails potential of drug that treats fatal childhood disease

“The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy,” said boss Glyn Edwards
boy walking a boardwalk
Duchenne muscular dystrophy is a fatal muscle-wasting disease that affects boys

Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) chief executive Glyn Edwards believes the company’s phase II drug could be the new standard of care for children with Duchenne muscular dystrophy, a fatal muscle-wasting disease that affects boys.

His assessment of the potential of ezutromid followed the release of 24-week data from the company’s clinical study of the treatment, which revealed a statistically significant and meaningful reduction in both muscle damage and inflammation.

READ: Summit Therapeutics discovers new potential antibiotics for gonorrhoea

“The strength of the interim data from our PhaseOut DMD trial has bolstered our belief that ezutromid could become a new standard of care for all patients with Duchenne muscular dystrophy,” Edwards said in an update alongside the company’s first-quarter results.

The read-out from the completed second-phase trial is expected in the third-quarter.

The company’s second drug, next-generation antibiotic ridinilazole, is expected to undergo a phase III trial in the first three months of next year.

Financially, Summit is in a strong position. A £15mln share placing helped bolster Summit’s bank balance, which was £27.7mln at the end of April. The company posted a loss of £5.8mln for the three months ended April 30.

 

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use